The estimated Net Worth of Joshua Lehrer Graiwer is at least $637 Tysiąc dollars as of 5 March 2020. Joshua Graiwer owns over 2,076 units of Global Blood Therapeutics stock worth over $177,732 and over the last 5 years Joshua sold GBT stock worth over $459,600.
Joshua has made over 11 trades of the Global Blood Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Joshua sold 2,076 units of GBT stock worth $130,497 on 5 March 2020.
The largest trade Joshua's ever made was exercising 22,523 units of Global Blood Therapeutics stock on 25 November 2019 worth over $971,192. On average, Joshua trades about 5,449 units every 9 days since 2019. As of 5 March 2020 Joshua still owns at least 2,595 units of Global Blood Therapeutics stock.
You can see the complete history of Joshua Graiwer stock trades at the bottom of the page.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... oraz Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: